Biologics for Immuno-Oncology
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
25
NCT03895996
Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jun 20, 2019
Completion: Dec 19, 2023
Loading map...